29,250 Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Acquired by Prosperity Wealth Management Inc.

Prosperity Wealth Management Inc. bought a new position in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 29,250 shares of the company’s stock, valued at approximately $86,000.

Several other large investors have also added to or reduced their stakes in the business. R Squared Ltd acquired a new stake in Vistagen Therapeutics during the fourth quarter worth approximately $25,000. Virtu Financial LLC grew its stake in Vistagen Therapeutics by 30.5% during the third quarter. Virtu Financial LLC now owns 20,210 shares of the company’s stock worth $61,000 after purchasing an additional 4,722 shares during the period. Jane Street Group LLC acquired a new stake in Vistagen Therapeutics during the third quarter worth approximately $59,000. HighTower Advisors LLC acquired a new stake in Vistagen Therapeutics during the third quarter worth approximately $64,000. Finally, Valence8 US LP acquired a new stake in Vistagen Therapeutics during the third quarter worth approximately $103,000. Institutional investors and hedge funds own 78.39% of the company’s stock.

Vistagen Therapeutics Price Performance

NASDAQ VTGN opened at $2.79 on Thursday. Vistagen Therapeutics, Inc. has a one year low of $2.22 and a one year high of $5.74. The business has a 50 day simple moving average of $2.87 and a 200 day simple moving average of $2.91. The stock has a market capitalization of $80.52 million, a P/E ratio of -1.89 and a beta of 0.62.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Thursday, February 13th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.02. Vistagen Therapeutics had a negative return on equity of 48.12% and a negative net margin of 6,777.08%. The firm had revenue of $230 billion during the quarter, compared to analysts’ expectations of $0.18 million. Equities analysts expect that Vistagen Therapeutics, Inc. will post -1.77 earnings per share for the current year.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.